patients experienced objective tumor regression with equal frequency while receiving the aminoglutethimide-hydrocortisone regimen or aminoglutethimide and dexamethasone and the overall rate of response in 50 evaluable patients was 38 % .
C0392969
aminoglutethimide-hydrocortisone
C0002555
aminoglutethimide